Medfinder
Back to blog

Updated: January 25, 2026

What Is Olumiant? Uses, Dosage, and What You Need to Know in 2026

Author

Peter Daggett

Peter Daggett

Medication bottle with educational information icon representing Olumiant drug guide

Olumiant (baricitinib) is an oral JAK inhibitor approved for RA, alopecia areata, and COVID-19. Here's everything you need to know about uses, doses, and more.

If you or someone you care about has been prescribed Olumiant (baricitinib), or if you're researching treatment options for rheumatoid arthritis or alopecia areata, this guide has what you need. We'll cover what Olumiant is, what it's approved to treat, how to take it, and what to expect.

What Is Olumiant?

Olumiant is the brand name for baricitinib, an oral medication developed by Incyte and licensed to Eli Lilly for commercialization. It belongs to a drug class called Janus kinase (JAK) inhibitors — medications that work by blocking specific proteins in your immune system that trigger inflammation.

Olumiant comes as a small oral tablet taken once daily with or without food. It comes in three strengths: 1 mg, 2 mg, and 4 mg.

What Is Olumiant FDA-Approved to Treat?

As of 2026, Olumiant has three FDA-approved indications:

1. Rheumatoid Arthritis (RA): FDA-approved in May 2018 for adults with moderately to severely active RA who have had an inadequate response to one or more TNF blocker therapies (like adalimumab/Humira or etanercept/Enbrel).

2. Severe Alopecia Areata: FDA-approved in June 2022 as the first and only systemic treatment for severe alopecia areata in adults. In clinical trials, 35–40% of patients treated with baricitinib achieved a SALT score of 20 or less (indicating 80% or more scalp hair coverage) at 36 weeks.

3. COVID-19: FDA-approved in May 2022 for hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This was the first immunomodulatory treatment for COVID-19 to receive full FDA approval.

Olumiant Dosage: How Much Should You Take?

Dosing depends on your condition:

Rheumatoid arthritis: 2 mg once daily. This is the only approved dose for RA in the United States.

Alopecia areata: Start at 2 mg once daily. Your doctor may increase to 4 mg if response is inadequate. For patients with nearly complete or complete scalp hair loss, 4 mg/day is recommended as the starting dose. Once adequate response is achieved on 4 mg/day, the dose is decreased to 2 mg/day.

COVID-19: 4 mg once daily for up to 14 days or until hospital discharge, whichever comes first.

Dose adjustments: If you're taking probenecid (a gout medication that is a strong OAT3 inhibitor), your doctor should reduce your baricitinib dose to 1 mg/day. If your kidney function is impaired (eGFR < 60 mL/min/1.73 m²), Olumiant is generally not recommended.

How to Take Olumiant

Take Olumiant exactly as prescribed — once daily, at the same time each day if possible

Can be taken with or without food — having it with food may reduce nausea

Swallow the tablet whole — do not crush or split it

If you miss a dose, take it as soon as you remember — unless it's almost time for your next dose, in which case skip the missed dose and resume your regular schedule

Store at room temperature between 68°F–77°F (20°C–25°C) in a cool, dry place

Who Should NOT Take Olumiant?

Olumiant is not appropriate for everyone. Do NOT take Olumiant if you:

Have an active serious infection, including active tuberculosis

Are pregnant or planning to become pregnant (animal studies show fetal harm)

Are breastfeeding (avoid and for 4 days after the last dose)

Have severely reduced kidney function (eGFR < 60 mL/min/1.73 m²)

Have very low blood cell counts (ALC < 500 cells/mm³, ANC < 1000 cells/mm³, or Hgb < 8 g/dL)

How Long Does It Take for Olumiant to Work?

For rheumatoid arthritis, some patients see symptom improvement as early as Week 1, with more significant improvements in disease activity scores by Week 12. For alopecia areata, hair regrowth typically takes longer — most patients require 24–36 weeks of treatment to see significant scalp coverage. Clinical trials showed 35–40% of patients achieving ≥80% scalp hair coverage at 36 weeks with baricitinib.

Is Olumiant Available as a Generic?

No. As of 2026, baricitinib is only available under the brand name Olumiant in the United States. Patent protections extend through the mid-to-late 2020s. There is no FDA-approved generic version available domestically. International generic versions exist in some countries but cannot be legally imported for personal use in the U.S.

Getting Your Prescription Filled

Olumiant is only available at specialty pharmacies — not standard retail chains. If you're having trouble finding it, use medfinder to locate a specialty pharmacy with it in stock. For cost strategies, check out our guide on how to save money on Olumiant in 2026.

Frequently Asked Questions

Olumiant (baricitinib) is FDA-approved for three conditions: (1) moderately to severely active rheumatoid arthritis in adults who haven't responded to TNF blockers, (2) severe alopecia areata in adults, and (3) COVID-19 in hospitalized adults requiring breathing support. It is a JAK inhibitor that works by suppressing overactive immune signaling.

For rheumatoid arthritis, the standard dose is 2 mg once daily. For alopecia areata, most patients start at 2 mg once daily, with possible increase to 4 mg if needed. For patients with nearly complete hair loss, 4 mg/day is recommended upfront. For COVID-19, the dose is 4 mg once daily for up to 14 days or until hospital discharge.

For alopecia areata, most patients require 24–36 weeks of treatment to see significant hair regrowth. Clinical trials showed 35–40% of patients achieving ≥80% scalp hair coverage at 36 weeks. Some patients see earlier improvement, but full response requires patience. For RA, symptom improvement can begin as early as Week 1.

Yes. Olumiant can be taken with or without food. If you experience nausea, taking it with food may help. Take it at the same time each day, swallow the tablet whole, and store at room temperature.

No. As of 2026, there is no FDA-approved generic baricitinib available in the United States. Patent protections for Olumiant extend through the mid-to-late 2020s. Until a generic becomes available, all U.S. patients must use Eli Lilly's branded Olumiant.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Olumiant also looked for:

30,258 have already found their meds with Medfinder.

Start your search today.

30K+
5-star ratingTrusted by 30,258 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?